Literature DB >> 28137478

Gender balance in patients with systemic lupus erythematosus.

Audrey A Margery-Muir1, Christine Bundell2, Delia Nelson3, David M Groth4, John D Wetherall5.   

Abstract

Factors are reviewed that contribute to the contemporary view of a disproportionate prevalence and incidence of SLE in females. Recent studies on the epidemiology of SLE report that global incidences and prevalences of SLE for Caucasian and Black populations are of the order of 5.5 and 13.1 per year and 81 and 212 per 100,000 persons respectively. Both parameters displayed age dependent variation over a 90-year lifespan. The female to male (F:M) incidence of SLE varied with age, being approximately 1 during the first decade of life, followed by a sharp increase to 9 during the 4th decade, thence declining in subsequent decades before an increase during the 7th or 8th decade. A cognate review of SLE diagnosis in neonates revealed a F:M ratio of ≈1.2, consistent with the epidemiology review and the sporadic nature of SLE. Notional estimates of disease duration showed a steady increase from a base level for both males and females. The linear trend line for males was always lower than the trend line for females, supporting clinical experience that SLE is a more severe disease in males. Over a 14-year interval ending in 2012, the notional duration of SLE increased from 10-15years to 20-25years, probably reflecting advances in diagnosis and clinical practice. A metastudy of SLE concordance in twins revealed a 75% discordance in monozygotic twins compared to a 95% discordance in dizygotic twins confirming the importance of environmental factors in susceptibility to SLE. The elevated discordance in dizygotic SLE twins (and between siblings) suggests a role for the intrinsic genomic sexual dimorphism due to divergence of Y chromosome regulatory loci from their X chromosome homologues due to lack of recombination of mammalian sex chromosomes over evolutionary time. Estimates were made of the incidences of SLE in males and females based on population data for nine autosomal deficiency loci of major effect, plus expected male prevalence associated with Klinefelter's syndrome and female prevalence associated with Triple X syndrome. These genetic abnormalities accounted for ≈4% of female and ≈23% of male Caucasoid prevalence and for SLE resulting in a F:M ratio of ≈0.17. It may be deduced therefore that the impressive preponderance of SLE in females arises from a combination of environmental triggers and susceptibility loci of relatively small effect acting between the interval from the mini-puberty of childhood to the peak of reproductive adulthood. It is in this cohort of females, and especially in the Black population, that combinations of loci of minor effect acting together with environmental factors initiate defective apoptosis resulting in consequential autoimmune disease especially SLE. We postulate that because apoptosis is itself a very complex process, and defective apoptosis is an important contributor to SLE, there will be many combinations of susceptibility loci and environmental stimuli that can result in SLE (and other autoimmune disease(s)), of varying severity.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28137478     DOI: 10.1016/j.autrev.2017.01.007

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  21 in total

1.  Diagnostic value of trait antinuclear antibodies and multiple immunoglobulin production in autoimmune diseases.

Authors:  Liping Wan; Hong Zhu; Yanan Gu; Hui Liu
Journal:  J Clin Lab Anal       Date:  2017-11-23       Impact factor: 2.352

2.  Autoimmune potential of perchloroethylene: Role of lipid-derived aldehydes.

Authors:  Gangduo Wang; Jianling Wang; G A Shakeel Ansari; M Firoze Khan
Journal:  Toxicol Appl Pharmacol       Date:  2017-08-14       Impact factor: 4.219

Review 3.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset.

Authors:  Kunihiro Hayakawa; Maki Fujishiro; Yuko Yoshida; Yuko Kataoka; Shota Sakuma; Takuya Nishi; Keigo Ikeda; Shinji Morimoto; Kenji Takamori; Iwao Sekigawa
Journal:  Clin Exp Immunol       Date:  2022-05-13       Impact factor: 4.330

5.  Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.

Authors:  Rahul M Kakalij; Del L Dsouza; Erika I Boesen
Journal:  Front Physiol       Date:  2022-07-06       Impact factor: 4.755

6.  Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset.

Authors:  Kunihiro Hayakawa; Maki Fujishiro; Yuko Yoshida; Yuko Kataoka; Shota Sakuma; Takuya Nishi; Keigo Ikeda; Shinji Morimoto; Kenji Takamori; Iwao Sekigawa
Journal:  Clin Exp Immunol       Date:  2022-02-02       Impact factor: 5.732

7.  Systemic lupus erythematosus as a genetic disease.

Authors:  Isaac T W Harley; Amr H Sawalha
Journal:  Clin Immunol       Date:  2022-02-09       Impact factor: 10.190

8.  Spectrum of systemic lupus erythematosus in Oman: from childhood to adulthood.

Authors:  Asma Al Rasbi; Eiman Abdalla; Rabab Sultan; Nasreen Abdullah; Juma Al Kaabi; Ibrahim Al-Zakwani; Reem Abdwani
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

9.  Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.

Authors:  Ahmed Nader; Mukul Minocha; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

10.  Interventions for cutaneous disease in systemic lupus erythematosus.

Authors:  Cora W Hannon; Collette McCourt; Hermenio C Lima; Suephy Chen; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.